AVM Biotechnology

company

About

AVM Biotechnology is a clinical stage company.

  • 11 - 50

Details

Last Funding Type
Grant
Last Funding Money Raised
$2M
Industries
Biotechnology,Medical,Pharmaceutical
Founded date
Jan 1, 2008
Number Of Employee
11 - 50
Operating Status
Active

AVM is a clinical-stage biotech company located in Seattle WA led by Dr. Theresa Deisher, a biotech veteran with a productive history including 47 patents and 4 discoveries in clinical trials. The company's lead drug AVM0703, an innovative formulation of dexamethasone, when given at suprapharmacologic doses has a novel mechanism of action to mobilize the body's own natural supercharged immune cells. AVM0703 could be the first choice for no-option cancer, autoimmunity, and infectious disease. AVM Biotechnology has a Scientific Advisory Board including well-respected leaders in cancer and immunology.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$2M
AVM Biotechnology has raised a total of $2M in funding over 2 rounds. Their latest funding was raised on Jun 14, 2022 from a Grant round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jun 14, 2022 Grant $2M 1 National Institutes of Health Detail
Jun 11, 2020 Grant 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
2
AVM Biotechnology is funded by 2 investors. National Institutes of Health and National Institutes of Health (NIH) are the most recent investors.
Investor Name Lead Investor Funding Round
National Institutes of Health Yes Grant
National Institutes of Health (NIH) Grant